SI2822590T1 - Formulacije s protitelesi proti IL-17 - Google Patents

Formulacije s protitelesi proti IL-17

Info

Publication number
SI2822590T1
SI2822590T1 SI201330364A SI201330364A SI2822590T1 SI 2822590 T1 SI2822590 T1 SI 2822590T1 SI 201330364 A SI201330364 A SI 201330364A SI 201330364 A SI201330364 A SI 201330364A SI 2822590 T1 SI2822590 T1 SI 2822590T1
Authority
SI
Slovenia
Prior art keywords
antibody formulation
antibody
formulation
Prior art date
Application number
SI201330364A
Other languages
English (en)
Inventor
Vincent John Corvari
Barbara Ann Williams
Patrick Daniel Donovan
Aaron Paul Markham
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI2822590T1 publication Critical patent/SI2822590T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201330364A 2012-03-07 2013-03-01 Formulacije s protitelesi proti IL-17 SI2822590T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607671P 2012-03-07 2012-03-07
PCT/US2013/028516 WO2013134052A1 (en) 2012-03-07 2013-03-01 Il-17 antibody formulation
EP13710214.1A EP2822590B1 (en) 2012-03-07 2013-03-01 Il-17 antibody formulation

Publications (1)

Publication Number Publication Date
SI2822590T1 true SI2822590T1 (sl) 2017-01-31

Family

ID=47892018

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330364A SI2822590T1 (sl) 2012-03-07 2013-03-01 Formulacije s protitelesi proti IL-17

Country Status (35)

Country Link
US (3) US9376491B2 (sl)
EP (2) EP2822590B1 (sl)
JP (1) JP6117252B2 (sl)
KR (1) KR101653082B1 (sl)
CN (1) CN104159612B (sl)
AU (1) AU2013230490B2 (sl)
BR (1) BR112014021308B1 (sl)
CA (1) CA2866128C (sl)
CL (1) CL2014002204A1 (sl)
CY (1) CY1118393T1 (sl)
DK (1) DK2822590T3 (sl)
EA (1) EA030742B1 (sl)
EC (1) ECSP14017562A (sl)
ES (1) ES2610707T3 (sl)
HK (1) HK1199844A1 (sl)
HR (1) HRP20161604T1 (sl)
HU (1) HUE031290T2 (sl)
IL (1) IL234053B (sl)
LT (1) LT2822590T (sl)
MA (1) MA37317B1 (sl)
ME (1) ME02565B (sl)
MX (1) MX362191B (sl)
MY (1) MY167233A (sl)
NZ (1) NZ627648A (sl)
PE (1) PE20142275A1 (sl)
PH (1) PH12014501985A1 (sl)
PL (1) PL2822590T3 (sl)
PT (1) PT2822590T (sl)
RS (1) RS55417B1 (sl)
SG (1) SG11201404491XA (sl)
SI (1) SI2822590T1 (sl)
TN (1) TN2014000341A1 (sl)
UA (1) UA114620C2 (sl)
WO (1) WO2013134052A1 (sl)
ZA (1) ZA201405654B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2019027828A1 (en) * 2017-08-04 2019-02-07 Eli Lilly And Company DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
JP7212675B2 (ja) 2017-08-23 2023-01-25 イーライ リリー アンド カンパニー 性器乾癬の治療
MX2017016884A (es) * 2017-12-19 2019-06-20 Probiomed S A De C V Formulacion farmaceutica estable de una proteina anti-tnfa.
CA3121288A1 (en) * 2018-11-29 2020-06-04 Harbour Biomed Therapeutics Limited Anti-pd-l1 antibody preparation
EP3927729A4 (en) * 2019-02-18 2023-10-11 Eli Lilly and Company THERAPEUTIC ANTIBODY FORMULATION
US20240052026A1 (en) * 2020-12-22 2024-02-15 Bio-Thera Solutions, Ltd. Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1963368E (pt) * 2005-12-13 2012-09-14 Lilly Co Eli Anticorpos anti-il-17
EA017549B1 (ru) * 2006-12-05 2013-01-30 Круселл Холланд Б.В. Стабильные жидкие композиции антител против вируса бешенства
SG182468A1 (en) * 2010-01-15 2012-08-30 Kirin Amgen Inc Antibody formulation and therapeutic regimens

Also Published As

Publication number Publication date
PE20142275A1 (es) 2015-01-08
CA2866128A1 (en) 2013-09-12
EP2822590B1 (en) 2016-10-26
SG11201404491XA (en) 2014-09-26
AU2013230490A1 (en) 2014-08-14
BR112014021308A2 (pt) 2017-07-04
HK1199844A1 (zh) 2015-07-24
MA37317B1 (fr) 2016-10-31
KR101653082B1 (ko) 2016-08-31
CY1118393T1 (el) 2017-06-28
ME02565B (me) 2017-02-20
PT2822590T (pt) 2016-12-15
TN2014000341A1 (en) 2015-12-21
JP6117252B2 (ja) 2017-04-19
CA2866128C (en) 2017-02-28
MY167233A (en) 2018-08-14
US20180057584A1 (en) 2018-03-01
US9376491B2 (en) 2016-06-28
EP2822590A1 (en) 2015-01-14
PH12014501985B1 (en) 2014-11-24
CN104159612B (zh) 2016-03-16
MX362191B (es) 2019-01-08
CN104159612A (zh) 2014-11-19
UA114620C2 (uk) 2017-07-10
AU2013230490B2 (en) 2017-04-13
KR20140120938A (ko) 2014-10-14
MX2014010710A (es) 2015-04-14
EP3156073A1 (en) 2017-04-19
PL2822590T3 (pl) 2017-06-30
NZ627648A (en) 2016-10-28
JP2015510882A (ja) 2015-04-13
MA37317A1 (fr) 2016-03-31
US20160280781A1 (en) 2016-09-29
IL234053A0 (en) 2014-09-30
ZA201405654B (en) 2016-05-25
US9845353B2 (en) 2017-12-19
US20150010573A1 (en) 2015-01-08
RS55417B1 (sr) 2017-04-28
EA030742B1 (ru) 2018-09-28
LT2822590T (lt) 2017-01-25
DK2822590T3 (en) 2017-01-23
IL234053B (en) 2018-06-28
EA201491471A1 (ru) 2014-12-30
CL2014002204A1 (es) 2015-01-30
HRP20161604T1 (hr) 2016-12-30
HUE031290T2 (hu) 2017-06-28
US10472416B2 (en) 2019-11-12
PH12014501985A1 (en) 2014-11-24
ECSP14017562A (es) 2015-09-30
ES2610707T3 (es) 2017-05-03
BR112014021308B1 (pt) 2022-08-30
WO2013134052A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
HK1203146A1 (en) Antibody formulation
PL3117837T3 (pl) Formulacje przeciwciała
HK1200717A1 (en) Abeta antibody formulation abeta
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
ZA201407316B (en) Anti-fgfr2 antibody
EP2892559A4 (en) ANTIBODY FORMULATIONS AND USES THEREOF
EP2826790A4 (en) GREMLIN-1 ANTIBODY
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
HK1199844A1 (zh) 抗體配方
HK1215796A1 (zh) 抗體製劑
GB201220242D0 (en) Antibody
EP2848633A4 (en) ANTI-CXADR ANTIBODY
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß